Jennifer N. Goldstein, MD, MSc

Human synthetic insulin may offer low-cost, effective treatment for certain patients with diabetes and financial constraints.

A care transitions program for patients who underwent percutaneous coronary intervention appeared to reduce 30-day rehospitalizations for patients with Medicaid who lived in wealthier zip codes.